完整標題：Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine
發稿單位：USA CDC &FDA
發稿時間：Tuesday, April 13, 2021
原文連結：https://www.cdc.gov/media/releases/2021/s0413-JJ-vaccine.html
The following statement is attributed to Dr. Anne Schuchat, Principal Deputy
Director of the CDC and Dr. Peter Marks, director of the FDA’s Center for
Biologics Evaluation and Research
As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen
) vaccine have been administered in the U.S. CDC and FDA are reviewing data
involving six reported U.S. cases of a rare and severe type of blood clot in
individuals after receiving the J&J vaccine. In these cases, a type of blood
clot called cerebral venous sinus thrombosis (CVST) was seen in combination
with low levels of blood platelets (thrombocytopenia). All six cases occurred
among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days
after vaccination. Treatment of this specific type of blood clot is different
from the treatment that might typically be administered. Usually, an
anticoagulant drug called heparin is used to treat blood clots. In this
setting, administration of heparin may be dangerous, and alternative
treatments need to be given.
CDC will convene a meeting of the Advisory Committee on Immunization
Practices (ACIP) on Wednesday to further review these cases and assess their
potential significance. FDA will review that analysis as it also investigates
these cases. Until that process is complete, we are recommending a pause in
the use of this vaccine out of an abundance of caution. This is important, in
part, to ensure that the health care provider community is aware of the
potential for these adverse events and can plan for proper recognition and
management due to the unique treatment required with this type of blood clot.
Right now, these adverse events appear to be extremely rare. COVID-19 vaccine
safety is a top priority for the federal government, and we take all reports
of health problems following COVID-19 vaccination very seriously. People who
have received the J&J vaccine who develop severe headache, abdominal pain,
leg pain, or shortness of breath within three weeks after vaccination should
contact their health care provider. Health care providers are asked to report
adverse events to the Vaccine Adverse Event Reporting System at
https://vaers.hhs.gov/reportevent.htmlexternal icon.
CDC and FDA will provide additional information and answer questions later
today at a media briefing. A recording of that media call will be available
on the FDA’s YouTube channel.
簡單整理:
在接種疫苗後三週內出現嚴重的頭痛，腹痛，大腿痛，胸悶或呼吸急促，應儘速就醫，
鑒於採用類似技術的AZ也有類似關聯性出現，
有打AZ疫苗的出現類似情形最好也趕快就醫~~
另外，常見的肝素治療血栓在該情形不建議